別孕烷醇酮

別孕烷醇酮
臨床資料
商品名（英語：Drug nomenclature）	Zulresso
其他名稱	ALLO; Allo; ALLOP; AlloP; Brexanolone; SAGE-547; SGE-102; 5α-Pregnan-3α-ol-20-one; 3α-Hydroxy-5α-pregnan-20-one; 3α,5α-Tetrahydroprogesterone; 3α,5α-THP
給藥途徑	Intravenous infusion
藥物類別（英語：Drug class）	Neurosteroids; Antidepressants
法律規範狀態
法律規範	美：處方藥（℞-only）;
藥物動力學數據
血漿蛋白結合率	>99%
藥物代謝	Non-CYP450 (keto-reduction via AKRs, glucuronidation via UGTs, sulfation via SULTs)
生物半衰期	9 hours
排泄途徑	Feces: 47%; Urine: 42%
識別資訊
	IUPAC命名法 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone; OR; 1-[(1S,2S,5R,7S,10R,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadec-14-yl]ethanone; ;
CAS號	516-54-1
PubChem CID	92786;
DrugBank	DB11859;
ChemSpider	83760;
UNII	S39XZ5QV8Y;
KEGG	D11149;
ChEBI	CHEBI:50169;
ChEMBL	ChEMBL207538;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID1046342、DTXSID901016239 ;
化學資訊
化學式	C21H34O2
摩爾質量	318.501 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C;
	InChI InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1; Key:AURFZBICLPNKBZ-SYBPFIFISA-N;

別孕烷醇酮（英語：allopregnanolone，ALLO，也名為3α,5α-孕烷醇酮）是一種作用於大腦的神經甾體^[2]^[3]，可用於治療產後抑鬱症^[3]^[4]^[5]。

參考文獻

^ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 存档副本 (PDF). [2019-05-26]. （原始內容存檔 (PDF)於2020-11-12）.
^ Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Progress in Brain Research 186. 2010: 113–37. ISBN 9780444536303. PMC 3139029  . PMID 21094889. doi:10.1016/B978-0-444-53630-3.00008-7. |journal=被忽略 (幫助)
^ ^3.0 ^3.1 Commissioner, Office of the. Press Announcements - FDA approves first treatment for post-partum depression. www.fda.gov. [21 March 2019]. （原始內容存檔於2019-04-22）（英語）.
^ Frieder A, Fersh M, Hainline R, Deligiannidis KM. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. CNS Drugs. March 2019, 33 (3): 265–282. PMID 30790145. doi:10.1007/s40263-019-00605-7.
^ Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov. Today. February 2019, 24 (2): 606–615. PMID 30447328. doi:10.1016/j.drudis.2018.11.007.